Introduction
Menstrual migraine is a big challenge for the migraine expert. Severity and duration of hormonal stimulation determines the gravity and duration of menstrual attack.
Various prevention therapy try to alleviate these attacks, usually long half-life triptans and-or anti-inflammatory drugs, combined with caffeine, magnesium, but however is very difficult to find the right drug in particular in women with uterine fibroids or endometriosis.
Anzeige
Aims
To support this limited class of patients, we considered to use the Oxycodone/Naloxone Extended Release (O/N-ER) for its favourable mechanism of action on neuropathic pain, long half life and well documented gastrointestinal safety. Although the drug has an indication for chronic pain, many reports in literature support its use in acute pain.
Methods
Recruitment is only for patients non-responders to classical preventive therapy. Will be collected informed consent, headache diary and a satisfaction questionnaire on therapy, those data will compared with the one recorded in the previous quarter, pharmacoeconomic analysis will provided.
Patients will use O/N-ER exclusively for menstrual attacks and for three consecutive periods, with the possibility of use a triptan at the start of attack followed by O/N-ER bid for 3-5 days.
Results
Of the 8 patients that have completed the study (12 patients are ongoing in the trial), 70% of the patients showed a mean reduction in intensity of attacks from 8 to 4 on a NRS scale, grade of satisfaction was 8/10, without significant side effects. More data will come from the analysis of the entire group of the enrolled patients.
Anzeige
No conflict of interest.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.